)
Samsung Epis Holdings (0126Z0) investor relations material
Samsung Epis Holdings Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue and operating profit rose YoY and QoQ at the biosimilar operating business, supported by product sales and milestone inflows; consolidated operating profit was lower after non-cash accounting adjustments.
YTD revenue and operating profit increased, with full-year revenue and operating profit expected to exceed the prior year and operating margin above 20%.
Financial highlights
Q3 consolidated revenue was KRW442B and operating profit KRW105B; YTD revenue was KRW1,288B and operating profit KRW254B.
Q3 biosimilar business revenue was KRW442B, up 0.3% YoY and 13% QoQ; operating profit was KRW133B, up 3% YoY and 53% QoQ.
YTD biosimilar business revenue reached KRW1,289B, up 4% YoY, and operating profit KRW363B, up 5% YoY.
Outlook and guidance
2026 revenue and operating profit are expected to exceed prior-year levels, with operating margin of 20%+.
Targeting 10+ biosimilar products in the development pipeline by 2030 and at least one ADC candidate IND submission annually from 2027.
Strategic objectives include near-term No. 1 market share in the EU and No. 2 in the US.
- H1 2026 revenue hit KRW 845.8B, with 21.9% net margin and robust biosimilar export growth.0126Z0
Q2 2026 - Bioepis delivered robust Q4 and FY 2025 growth, while Holdings faced short-term losses.0126Z0
Q4 2025 - Q1 2026 delivered double-digit biosimilar-driven growth, strong margins, and global expansion.0126Z0
Q1 2026
Next Samsung Epis Holdings earnings date
Next Samsung Epis Holdings earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)